Department of Medicine, Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts;, †Department of Pathology, Division of Clinical Chemistry and, ‡Department of Medicine, Division of Nephrology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Clin J Am Soc Nephrol. 2013 Nov;8(11):1927-34. doi: 10.2215/CJN.04310413. Epub 2013 Aug 22.
The mechanisms underlying erythropoietin resistance are not fully understood. Carbamylation is a post-translational protein modification that can alter the function of proteins, such as erythropoietin. The hypothesis of this study is that carbamylation burden is independently associated with erythropoietin resistance.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a nonconcurrent prospective cohort study of incident hemodialysis patients in the United States, carbamylated albumin, a surrogate of overall carbamylation burden, in 158 individuals at day 90 of dialysis initiation and erythropoietin resistance index (defined as average weekly erythropoietin dose [U] per kg body weight per hemoglobin [g/dl]) over the subsequent 90 days were measured. Linear regression was used to describe the relationship between carbamylated albumin and erythropoietin resistance index. Logistic regression characterized the relationship between erythropoietin resistance index, 1-year mortality, and carbamylation.
The median percent carbamylated albumin was 0.77% (interquartile range=0.58%-0.93%). Median erythropoietin resistance index was 18.7 units/kg per gram per deciliter (interquartile range=8.1-35.6 units/kg per gram per deciliter). Multivariable adjusted analysis showed that the highest quartile of carbamylated albumin was associated with a 72% higher erythropoietin resistance index compared with the lowest carbamylation quartile (P=0.01). Increasing erythropoietin resistance index was associated with a higher risk of death (odds ratio per unit increase in log-erythropoietin resistance index, 1.69; 95% confidence interval, 1.06 to 2.70). However, the association between erythropoietin resistance index and mortality was no longer statistically significant when carbamylation was included in the analysis (odds ratio, 1.44; 95% confidence interval, 0.87 to 2.37), with carbamylation showing the dominant association with death (odds ratio for high versus low carbamylation quartile, 4.53; 95% confidence interval, 1.20 to 17.10).
Carbamylation was associated with higher erythropoietin resistance index in incident dialysis patients and a better predictor of mortality than erythropoietin resistance index.
促红细胞生成素抵抗的机制尚未完全阐明。氨甲酰化是一种翻译后蛋白质修饰,可改变蛋白质的功能,如促红细胞生成素。本研究的假设是,氨甲酰化负担与促红细胞生成素抵抗独立相关。
设计、设置、参与者和测量:在美国进行的一项非同期前瞻性队列研究中,研究了 158 名新开始透析的患者在透析开始后第 90 天的白蛋白氨甲酰化(整体氨甲酰化负担的替代指标)和随后 90 天内每周平均促红细胞生成素剂量[U]与体重每克血红蛋白[g/dl]的比值(定义为促红细胞生成素抵抗指数)。线性回归用于描述白蛋白氨甲酰化与促红细胞生成素抵抗指数之间的关系。逻辑回归描述了促红细胞生成素抵抗指数、1 年死亡率和氨甲酰化之间的关系。
中位白蛋白氨甲酰化百分比为 0.77%(四分位间距=0.58%-0.93%)。中位促红细胞生成素抵抗指数为 18.7 单位/kg 每克每分升(四分位间距=8.1-35.6 单位/kg 每克每分升)。多变量调整分析表明,与最低氨甲酰化四分位数相比,白蛋白氨甲酰化最高四分位数的促红细胞生成素抵抗指数高 72%(P=0.01)。促红细胞生成素抵抗指数的增加与死亡风险增加相关(每单位对数促红细胞生成素抵抗指数增加的优势比,1.69;95%置信区间,1.06 至 2.70)。然而,当分析中包括氨甲酰化时,促红细胞生成素抵抗指数与死亡率之间的关联不再具有统计学意义(优势比,1.44;95%置信区间,0.87 至 2.37),氨甲酰化与死亡的关联更为显著(高氨甲酰化四分位数与低氨甲酰化四分位数的优势比,4.53;95%置信区间,1.20 至 17.10)。
在新开始透析的患者中,氨甲酰化与更高的促红细胞生成素抵抗指数相关,并且是死亡率的更好预测指标,优于促红细胞生成素抵抗指数。